INDA

RBX2660-Rebiotix Receives FDA IND Approval to Begin Phase 2 Trial of Pioneering Microbiota Restoration Therapy

Posted on Updated on

RBX2660

Rebiotix Receives FDA IND Approval to Begin Phase 2 Trial of Pioneering
The Herald | HeraldOnline.com
Rebiotix Inc. announced today that the U.S. Food and Drug Administration has approved the company’s Investigational New Drug (IND) application to begin the Phase 2 clinical study of RBX2660 for the treatment of recurrent Clostridium difficile infection http://www.heraldonline.com/2013/07/29/5064322/rebiotix-receives-fda-ind-approval.html

CLOSTRIDIUM

Advertisements